ACIP Recommends Pfizer-BioNTech COVID-19 Vaccine for Children Aged 5-11 Years

This report describes a recommendation from the Advisory Committee on Immunization Practices (ACIP) for the use of the Pfizer-BioNTech COVID-19 vaccine in children aged 5-11 years in the United States. The publication type is listed as 'OTHER,' and it does not present new clinical trial data. No study type, phase, sample size, comparator, primary or secondary outcomes, or follow-up duration are reported. The report does not include any main results, such as vaccine efficacy or immunogenicity data. Safety and tolerability information, including adverse events, serious adverse events, and discontinuations, are also not reported. No specific study limitations are listed, and funding or conflict of interest disclosures are not provided. The practice relevance is explicitly stated as describing the ACIP recommendation. This is a policy announcement. Clinicians should refer to the full ACIP recommendation and the underlying evidence from the FDA's review for specific data on safety, efficacy, and implementation details before making clinical decisions.